Judith Koliwer

After her PhD on the genetic background of autism spectrum disorders, Judith was leading an academic research group, which analyzed the physiological role of proteins associated with cancer and epilepsy by using lenti and retroviral transduction for genetic modification of cell cultures. As the leading scientist for BSL2, she supported the development of all virus-based projects of the university. In 2019, Judith joined the MES Company Werum IT Solutions GmbH, now known as Körber Pharma Software GmbH, where she works as principal consultant for cell and gene therapy projects. She works closely together with cell and gene therapy / ATMP manufacturers, supporting them in transitioning their manufacturing process from paper to a digital solution.